...at the end of each section align wording and ideas back to the say-it sentence. Edit your papers to ensure that this organizational alignment happens and be more specific with your sources than this writer was. More comment about the source appears below. Alex _______ Assignment #3: Research Report November 15, 2012 Attempting to establish an internship with Pfizer Inc at this point in time is not in the best interest of Daniel University or its students. The first reason that makes Pfizer Inc. a less than ideal match for Daniel University's internship program is its history of ethical misconduct, especially bribery. In addition, the loss of market exclusivity of Lipitor has resulted in a sharp decline in sales as cheaper generic options have cut into Pfizer's market share. Finally, the decline in sales as a result of the loss of market exclusivity on drugs such as Lipitor has forced Pfizer Inc to resort to drastic cost cutting measures, which may hamper the company's growth potential in the long run and leave post-internship employment prospects for Daniel University students bleak. History of Ethical Misconduct Pfizer Inc has a history of ethical misconduct which heavily incorporates bribery of foreign officials and physicians. Kara Brockmeyer, chief of the division of the S.E.C. that enforces the Foreign Corrupt Practices Act (FCPA) has been quoted stating that, “Pfizer subsidiaries in several countries had bribery so entwined in their sales culture that they...
Words: 886 - Pages: 4
...organization’s SWOT where clear guidelines identify areas of focus. Achieving this requires innovation and alliances on products and services that will create a competitive advantage. Successfully execution requires a strategic manager who can effectively and successfully drive strategic objectives, then report its performance to the leadership team (Thompson & Strickland, 2013). This paper will examine how Pfizer utilized growth, innovation and execution strategies as well as acquisitions and mergers to become the number one global pharmaceutical company. The organization’s SWOT analysis (Thompson & Strickland, 2013) showed its strength in being innovative, opportunities to create more products, weakness in its dependence on successful products, and threats in generic competition and regulatory laws. The company’s corporate culture, strategic innovative through the top-down leadership approach, a unified tagline “OWN IT!” (Pfizer, 2013), and a strategy map demonstrates that all employees are ultimately responsible for their individual roles to drive success throughout the organization. Additionally, this paper will present a student created strategy map identifying areas the organization reports on annually. Theory Definitions Thompson and Strickland (2013) define that growth strategies arise when an organization utilizes its strength, weakness, opportunities, and threat (SWOT) to create a competitive advantage with customers, products and location. Pfizer’s SWOT analysis shows strong...
Words: 4579 - Pages: 19
... The subject of this paper is the quality management of two pharmaceutical companies, Pfizer and Johnson & Johnson. The two companies are said to provide the best possible care to the consumer in areas of health in the global market as well as the domestic market. Effects of Quality Management on Domestic and Global Competition The subject of this paper is on the pharmaceutical company of Pfizer pharmaceuticals and the Johnson & Johnson Company. Both companies are well known in the drug industry and both have the capacity to provide products for the domestic market and the global market. Both companies can provide health care for the population and to help find new drugs to provide the care of the population, which both the global and domestic markets need. Effects of Quality Management Pfizer Pfizer can develop resources to help people understand their illnesses, and the risks and benefits of the medicines available to treat them. Pfizer provides a patient assistance program to help the population that cannot afford medicines on his or her own to take control of his or her health (Pfizer, 2011) Pfizer has a product pipeline to help in the research and development of medicines to help with illness and diseases such as cardiovascular and metabolic diseases, immunology, and inflammation, neuroscience, vaccines, and pain (Pfizer, 2011). The products are approved by the FDA (Food and Drug Administration). According to Pfizer, “The Global Health Fellows...
Words: 726 - Pages: 3
...Pfizer Pharmaceuticals Submitted By: Latrell Jackson December 16, 2013 Submitted To: Dr. Diane Hamilton BA 530 Pfizer Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol); Lyrica (pregabalin, for neuropathic pain/fibromyalgia); Diflucan (fluconazole, an oral antifungal medication); Zithromax (azithromycin, an antibiotic); Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib, an anti-inflammatory drug) (Pfizer, 2010). Pfizer is made up of three main divisions; pharmaceutical, animal health, and research & development divisions. This paper will focus on the pharmaceutical division, with the emphasis on Viagra, which markets prescription and over the counter medications (Pfizer, 2010). Pfizer’s Pharmaceuticals segment includes its human pharmaceuticals and animal health businesses, as well as Capsugel, a producer of two-piece capsules used in manufacturing prescription and over-the-counter pharmaceuticals and nutritional supplements (Pfizer, 2010). Most of the company’s human pharmaceutical revenues come from products in three major therapeutic classes: cardiovascular diseases, infectious diseases, and central nervous system disorders. The company also has products for the treatment of diabetes, erectile...
Words: 826 - Pages: 4
...Secretary of Defense Corporate Fellows Program FINAL REPORT PFIZER, INC. LTC David J. Clark, USA April 2003 USAWC CIVILIAN RESEARCH PROJECT Product Counterfeiting in China and One American Company’s Response A Case Study and research report on corporate activity relating to national security and strategy Prepared for the Director of the Secretary of Defense Corporate Fellowship Program by David J. Clark Lieutenant Colonel United States Army Secretary of Defense Corporate Fellow Dr. Clayton Chun Project Advisor The views expressed in this academic research paper are those of the author and do not necessarily reflect the official policy or position of the U.S. Government, the Department of Defense, or any of its agencies. It also does not reflect any policy or position of Pfizer Incorporated. U.S. Army War College Carlisle Barracks, Pennsylvania 17013 - This Page Intentionally Left Blank - ABSTRACT AUTHOR: Lieutenant Colonel David J. Clark TITLE: Product Counterfeiting in China and One American Company’s Response FORMAT: Civilian Research Project DATE: 4 April 2003 PAGES: 36 CLASSIFICATION: Unclassified When America, the world’s largest economy, interacts with China, the world’s most populated country, matters of strategic and global importance are inevitably raised. Using his fellowship position in a major U.S. corporation as a vantage point, the author describes the impact...
Words: 8985 - Pages: 36
...Elwood Leftridge Professor Joanne Land Kazlauskas GPS-4278W 05-01-2013 Putting It All Together a Look at Pfizer Pharmaceutical Company Pfizer Pharmaceutical Company is not only the world’s largest research pharmaceutical company in the world, but also the leader of technological advances. This organization has been in operation for over 160 successful years, and has over 117,000 diverse workers employed worldwide from all facets of life. It is important to employ a solid employee workforce within an organization, this can either make or break an organization. “In 2012 Pfizer was ranked #40 among Fortune 500 with 2011 revenue totaling almost 68 million dollars, and a profit margin of over 10 million dollars”(CNN Money, 2013). The purpose of this paper is to break apart Pfizer into four different organizational perspectives, analyze them, and then put them back together again. Or as with the title of the textbook (Reframing Organizations: Artistry, Choice, and Leadership. Vol. 4) suggests to reframe organizations to a particular frame or frames. The frames that I will be using to analyze Pfizer Pharmaceuticals will be the Structural Frame, the Symbolic Frame, the Human Resources Frame, as well the Political Frame. To begin, I will describe the Pfizer organization using Bolman & Deal’s Structural Frame perspective. The structural components that I will discuss will be the Division of Labor, the Leadership Structure, and Roles and Responsibilities of the organization...
Words: 5349 - Pages: 22
...spending years of effort to integrate Warner Lambert and Pharmacia into Pfizer, should its management have avoided another huge acquisition like Wyeth? Should Pfizer have gone after smaller bio tech firms in a series of small acquisitions in 2008 and 2009? A number of these bio tech firms could have been acquired for the $68 billion price of the huge Wyeth acquisition. Present arguments for and against buying several small firms versus one large firm. In my opinion, when it comes to the option of bigger or smaller firm acquisition, Pfizer should have invested in a large acquisition like wryeth. This is because Pfizer’s focus is not really on how many firms it can acquire but proceeds and profit margins these acquisitions can bring in. Basing on the case, its previous large acquisitions such as Warner Lambert and Pharmacia. In 2000 and 2003 where quiet good investments bringing in large profit margin of up to 90% from the Warner. A large problem of staffing is also worsened by over acquisition. According to the case overtime acquired firms have brought in excess staff for Pfizer and this has become a problem as managers for each line have increased and thus larger costs in terms of salaries as well. Larger firm acquisitions have also evidently brought stronger products than Pfizer itself can produce. Drugs such as Lipitor from an acquired firm brought in sales of about 12 billion annually while Pfizer produced drugs have failed i.e. T-pill Furthermore larger acquisitions...
Words: 1587 - Pages: 7
...Assignment #1 Johnson & Johnson and Guidant FIN 648 February 13, 2006 Shreyasee Kothari Shalini Ramchandren Mattia Valdisolo William Smith Guidant, a company in the surgical & medical instruments & apparatus, is in the process of being acquired by Johnson & Johnson (J&J), a company that engages in the manufacturing and selling of various products in the health care field. By evaluating each company’s current strategy, it can help to decipher if J&J is undertaking a company that can add value to its business. Using several strategy models, such as Porter, Kauppi, the BCG Growth Matrix, and a Strength, Weakness, Opportunities, and Threats (SWOT) analysis for each company, we can identify how these companies operate in their own industries, as well as compare each to assess compatibility. Porter’s Model: 1. Barriers to Entry a. Regulatory restrictions: Guidant has extreme federal restrictions, as mandated by the industry it is in. By operating in the United States (US), Guidant must comply with the laws of the Federal Drug Agency (FDA). Operations in other countries (over 100) must comply with FDA equivalents in their respective countries. (Guidant 10-K 2004) Primary operations are in the US, Asia, and Europe. “The regulations also hold true for J&J due to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) that took effect on January 1, 2006. It will have a major impact on how drug companies negotiate...
Words: 3136 - Pages: 13
...All of the following medications are gluten free unless otherwise noted Generic drugs can be produced from many manufacturers and not all manufacturers use the same fillers or excipients. When there is a generic drug listed the manufacturer will be in the parenthesis. This does not imply that these are the only gluten free manufacturers but that these were the only ones checked. ANALGESICS/NONSTEROIDAL Acetaminophen w Codeine (Teva) Advil Aleve Alka Seltzer Gold Alka Seltzer Heartburn Relief Anaprox Anaprox DS Arthrotec Aspirin Enteric Coated 325mg (Leiner,code #44/227, Watson) Aspirin 81mg chewable (Watson) Avinza Baby aspirin (Walgreens, Perrigo) Bancaps HC Bufferin-all products EXCEPT Bufferin regular 325mg tablet which does contain some gluten Butazolidin Carisoprodol (Watson, West-Ward) Cataflam Celebrex Clinoril Cyclobenzaprine (Mylan, Schein, Watson) Daypro Demerol Durabac Ecotrin (all strengths) Endocet Endodan Esgic (all forms) Excedrin Extra Strength Excedrin Migraine Feldene-contains gluten Fioricet / with Codeine Fiorinal Fiorinal caps-generic (West-Ward) Fiorinal tabs-generic (West-Ward) Fiorinal with Codeine Flexeril Flubriprofen (Novapharm) Hydrocodone/APAP all strengths (Mallinckrodt, Watson) Ibuprofen (Amneal, Pharm. Formulations) Indocin Indomethacin (Novapharm) Ketoprofen XR (Andrx) Lodine (tabs/caps/XL) Lorcet 10/650 Lorcet Plus Lortab (all forms) Motrin Childrens DF Conc. Drops Mobic Morphine IR tabs (Roxane) Morphine Sulfate Ext Release Tab (Endo) Motrin...
Words: 2427 - Pages: 10
...Pfizer: Ethics and Leadership The selection process used by Pfizer to find a successor to CEO William Steere, who had lead the company to the top of the pharmaceutical industry, lacked a system of checks and balances resulting in a power struggle that ultimately led to distrust and the unraveling of Pfizer’s top brass by an outsider . The power struggle that erupted within Pfizer demonstrates how ethical breaches occur under specific conditions and the resulting damage. It is fascinating to observe how the unethical actions of a few individuals can spiral through an entire organization negatively affecting both the companies and their stakeholders. An economic analysis of Pfizer highlights the mismanagement of resources and the ensuing social and financial costs. Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart as a fine chemicals business in Brooklyn New York. In the 1950’s the company changed its focus from fine chemicals into a research based pharmaceutical company. Pfizer’s growth exploded in the 1980’s and 1990’s with the success of drugs like Lipitor and Viagra. Led by William Steere and fueled by profits from Lipitor, Pfizer was entering its glory years. Under Steere Pfizer stock rose to a record high of $49 a share. When Steere took control in 1991 his emphasis for Pfizer was research and development of pharmaceuticals. Pfizer became a benchmark in the pharmaceutical industry and “was ranked among America’s best managed and most admired companies...
Words: 2173 - Pages: 9
...Business Investigation of Pfizer Inc. World’s most profitable and privately sponsored research based biomedical organization is Pfizer Inc. Pfizer became the biggest pharmaceutical company after merging with Warner Lambert in the month of July, 2000. Huge global sales with a large number of popular products, a valuable and ingenious R&D division, all these have taken the firm to the peak of the industry. There lie some secrets behind the success of Pfizer that it follows while operating the business. They are: * Maximizing short and longstanding sales revenue. * Establishing a more flexible but lower cost base some places in Asia. * Creating smaller, more customer focused and responsible operating areas. * Engaging more customers, patients, tolerant, medical doctors and other collaborators. * Making Pfizer a place where everyone enjoys their job. Pfizer has altered the business method along with the change of the global business environment by the end of year 2007. This company currently operates in places where there are fewer constraints, less officialdom and minimum operating costs. Pfizer has reorganized their cost base to run with flexibility. Conversely, this company is now making things easier for the R&D division to create cooperation in all the research teams who are expert in different sides to increase efficiency by using all the research team in functioning together in any particular work base. The upward growth trend of pharmaceutical...
Words: 320 - Pages: 2
...Montagnola Managerial Accounting Individual Project When making my decision to obtain my PharmD. back in high school, I knew the world of opportunity that was awaiting me along with the chances to advance. However, when I decided to obtain my MBA in Healthcare Systems Management, another world of opportunity suddenly was placed in front of me. There are unlimited placements for a pharmacist in today’s society. Now when adding a MBA degree to my medical background, the placements seem endless. Mainly, numerous jobs in pharmaceutical companies suddenly become attainable and appealing. This is where the focus of my learning and goals has taken me, to be able to become an executive or director at a large pharmaceutical company, such as Pfizer or Merck. Nevertheless, much goes into a decision like this when weighing the options of accepting a job in this setting. How do I stand financially at this moment and current income? How would I stand if I were to accept the job offer that I have been offered? Does this company offer advancement for me to attain more prestigious and higher paying jobs? Does this company have a sustainable business model that will allow me to maintain a job for the future? As you can see, all these aspects play a role and that is only the tip of the inquiry. So how does one weigh the options of accepting a job offer knowing the circumstances in which they lie? I believe this process starts with determining the budget you are on at the moment and being able...
Words: 3185 - Pages: 13
...not sure about, note your assumption explicitly in your answer. A note of caution– while this case study may seem similar to the Zantac case, you should not assume that what was appropriate in that case is necessarily true here. Questions 1. What were the risks associated with the three specific actions (see p. 4) Warner-Lambert had taken during the development of Lipitor? Why did it take these actions? (10 points) 2. Do a SWOT (strength-weakness-opportunity-threat) analysis of Lipitor and Warner-Lambert (prior to the partnership with Pfizer). Also indicate what you think are the main challenges Lipitor’s marketing strategy should address (List no more than 3 challenges). (25 points) 3. Why did Warner-Lambert/Pfizer team up with the American Heart Association for the pre-launch advertising campaign even though it could not promote its brand name? (10 points) 4. What challenges are Warner-Lambert/Pfizer trying to overcome with the launch strategy they chose for Lipitor? (In your answer make sure you indicate: a. how Lipitor’s positioning for different targets and marketing mix decisions might overcome these challenges, and b. whether they are actually overcoming these challenges) (25 points) 5. How would you respond to...
Words: 365 - Pages: 2
...Executive Summary: Pfizer-Wyeth Merger Deal Overview: On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to receive, subject to adjustment under limited circumstances, a combination of $33.00 in cash, without interest, and 0.985 of a share of Pfizer common stock in a taxable transaction. Pfizer will not issue more than 19.9% of its outstanding common stock at the acquisition date in connection with the merger. The exchange ratio of 0.985 of a share of Pfizer common stock will be adjusted if the exchange ratio would result in Pfizer issuing in excess of 19.9% of its outstanding common stock as a result of the merger Deal Terms Breakdown: Transaction Value Transaction Consideration Purchase price per WYE share $50.19 Existing Cash Used $22,213 32.7% Cash per WYE share $33.00 New Debt $22,500 33.1% PFE stock value per WYE share $17.19 Total Cash $44,713 65.8% PFE shares per WYE share 0.985 Stock Consideration $23,289 34.2% Premium to 1/23/09 WYE price 29.3% Total Consideration $67,303 100.0% Total WYE shares (MM,diluted) 1,341 Total Equity...
Words: 8308 - Pages: 34
...Wang, she discusses a particular case in which Pfizer makes “…a deal with certain pharmacy benefit managers … to block generic versions of Lipitor.”(Wang, Pfizer’s Latest Twist on ‘Pay for Delay’) There are a few ethical issues with this: one, the rival companies are infringing on patent laws, two, larger pharmaceutical companies are trying to create as much profit for their company until their patent runs out, and three, Americans in need of the drug are forced to pay higher prices for their drugs. The latter two issues go hand in hand with one another. Patents are used to protect a company’s invention and gives the company exclusive rights to sell that invention. In this case the invention is a drug. But, in the drug business, companies can get a hold of a drug and break down the chemical components making it easy to duplicate. It is not right for competitive companies to be able to easily break down a drug when all the hard work has been done by another and profit. Just because there have been minor adjustments with the chemical structure of the drug gives the rival company the right to market and sell their product. At the same time doesn’t having the exclusive right to an invention like Lipitor create a monopoly for Pfizer? That is what a patent does, it gives the inventor the sole right to sell the product without interference from competitors until either the patent expires, or becomes obsolete. So, shouldn’t Pfizer be able to charge what the “feel” is right? Monopolies...
Words: 1413 - Pages: 6
